Optimind Pharma Corp. — Audit Report / Information 2022

Sep 13, 2022

OPTIMIND PHARMA CORP.

NOTICE OF CHANGE OF AUDITOR

TO: Ontario Securities Commission Alberta Securities Commission British Columbia Securities Commission Canadian Securities Exchange

PURSUANT TO Section 4.11 of National Instrument 51-102 Continuous Disclosure Obligations (" NI 51-102 "), Optimind Pharma Corp. (the " Company ") hereby provides notice that Harbourside CPA LLP (" Harbourside ") has resigned as auditor of the Company effective August 31, 2022 on its own initiative.

The Company's Board of Directors (the " Board ") is considering alternatives for a successor auditor to fill the vacancy in the position of auditor of the Company until the next annual general meeting of shareholders.

The Company confirms that:

1. the Company will appoint a replacement auditor to hold such position until the close of the next annual meeting of the shareholders of the Company;

2. on August 31, 2022 the Board, upon recommendation by the Audit committee of the Board, considered and approved the resignation of Harbourside as auditor of the Company;

3. the independent auditor's reports of Harbourside on the consolidated financial statements of the Company for the period ended from incorporation on December 16, 2020 to February 28, 2022 did not express a modified opinion; and

4. in the opinion of the Company, there have been no "reportable events" (as defined in NI 51-102).

DATED this 12[th] day of September, 2022.

OPTIMIND PHARMA CORP.

/s/ "Tom Sipos"

Per:

Tomas Sipos, President